Ultragenyx Pharmaceutical Inc.RARENASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 88% recommend buying.

Consensus Rating

Buy

24 analysts·High coverage

88%

Rating Distribution

Strong Buy

00%

Buy

2188%

Hold

28%

Sell

14%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 106% higher.

Bear Case

$44.00

+75%

Consensus

$51.57

+106%

Bull Case

$63.00

+151%

Price Range24 analysts

Low

Consensus

High

$44.00

$63.00

Current Target

Current Price

$25.08

Upside to Target

$26.49

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.78(13 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+42.05%

EPS—

FY2028

Rev+17.02%

EPS—

FY2029

Rev+34.64%

EPS+1110.99%

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-7.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 8, 2026Morgan Stanley

Ultragenyx price target lowered to $50 from $55 at Morgan Stanley

Target:$50.00

+106.6%from $24.20

Jan 5, 2026H.C. Wainwright

Ultragenyx price target lowered to $60 from $80 at H.C. Wainwright

Target:$60.00

+157.1%from $23.33

Jan 5, 2026Guggenheim

Ultragenyx price target lowered to $52 from $64 at Guggenheim

Target:$52.00

+120.3%from $23.60

Dec 30, 2025Wells Fargo

Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo

Target:$45.00

+128.2%from $19.72

Dec 30, 2025Jefferies

Ultragenyx price target lowered to $63 from $114 at Jefferies

Target:$63.00

+219.5%from $19.72

Dec 29, 2025Barclays

Ultragenyx price target lowered to $44 from $50 at Barclays

Target:$44.00

+123.1%from $19.72

Dec 29, 2025Robert W. Baird

Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird

Target:$47.00

+138.3%from $19.72

Dec 29, 2025Morgan Stanley

Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Target:$55.00

+183.9%from $19.37

Nov 24, 2025Barclays

Ultragenyx price target lowered to $50 from $81 at Barclays

Target:$50.00

+48.9%from $33.59

Mar 17, 2025Piper Sandler

Ultragenyx price target lowered to $115 from $140 at Piper Sandler

Target:$115.00

+190.1%from $39.64

Mar 7, 2025Morgan Stanley

Ultragenyx assumed with an Overweight at Morgan Stanley

Target:$64.00

+65.7%from $38.62

Nov 6, 2024H.C. Wainwright

Ultragenyx Pharma (RARE) PT Raised to $95 at H.C. Wainwright

Target:$95.00

+85.5%from $51.20

Nov 6, 2024Leerink Partners

Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Target:$85.00

+66.0%from $51.20

Jun 6, 2024Goldman Sachs

Goldman Sachs Upgrades Ultragenyx Pharma (RARE) to Buy

Target:$67.00

+61.6%from $41.45

May 31, 2024Stifel Nicolaus

Ultragenyx Pharma (RARE) PT Raised to $127 at Stifel

Target:$127.00

+228.6%from $38.65

May 31, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Target:$135.00

+249.3%from $38.65

May 31, 2024Robert W. Baird

Ultragenyx Pharma (RARE) PT Raised to $72 at Baird

Target:$72.00

+86.3%from $38.65

May 31, 2024Canaccord Genuity

Ultragenyx Pharma (RARE) PT Raised to $111 at Canaccord Genuity

Target:$111.00

+187.2%from $38.65

Apr 15, 2024Stifel Nicolaus

Stifel Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Target:$124.00

+189.2%from $42.87

Apr 15, 2024Raymond James

Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Target:$130.00

+203.2%from $42.87

Feb 3, 2023Morgan Stanley

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $95

Target:$95.00

+102.0%from $47.03

Dec 30, 2022H.C. Wainwright

HC Wainwright & Co. Assumes Ultragenyx Pharmaceutical at Buy, Announces Price Target of $82

Target:$82.00

+77.0%from $46.33

Jul 28, 2022Piper Sandler

Ultragenyx price target lowered to $130 from $135 at Piper Sandler

Target:$130.00

+150.6%from $51.88

Jul 1, 2022Stifel Nicolaus

Stifel Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $142

Target:$142.00

+138.0%from $59.66

May 24, 2022Goldman Sachs

Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $101

Target:$101.00

+113.9%from $47.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance